Search

Your search keyword '"Bertoletti A"' showing total 111 results
Start Over Author "Bertoletti A" Journal thrombosis research
111 results on '"Bertoletti A"'

3. Pulmonary embolism diagnostic strategies in patients with COPD exacerbation: Post-hoc analysis of the PEP trial

Author

Rambaud, Geoffroy, Mai, Vicky, Motreff, Camille, Sanchez, Olivier, Roy, Pierre-Marie, Auffret, Yannick, Le Mao, Raphael, Gagnadoux, Frédéric, Paleiron, Nicolas, Schmidt, Jeannot, Pastre, Jean, Nonent, Michel, Tromeur, Cécile, Salaun, Pierre-Yves, Mismetti, Patrick, Girard, Philippe, Lacut, Karine, Lemarié, Catherine A., Meyer, Guy, Leroyer, Christophe, Le Gal, Grégoire, Bertoletti, Laurent, and Couturaud, Francis

Published
2023
Full Text
View/download PDF

4. Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool

Author

Goedegebuur, J., Abbel, D., Accassat, S., Achterberg, W.P., Akbari, A., Arfuch, V.M., Baddeley, E., Bax, J.J., Becker, D., Bergmeijer, B., Bertoletti, L., Blom, J.W., Calvetti, A., Cannegieter, S.C., Castro, L., Chavannes, N.H., Coma-Auli, N., Couffignal, C., Edwards, A., Edwards, M., Enggaard, H., Font, C., Gava, A., Geersing, G.J., Geijteman, E.C.T., Greenley, S., Gregory, C., Gussekloo, J., Hoffmann, I., Højen, A.A., van den Hout, W.B., Huisman, M.V., Jacobsen, S., Jagosh, J., Johnson, M.J., Jørgensen, L., Juffermans, C.C.M., Kempers, E.K., Konstantinides, S., Kroder, A.F., Kruip, M.J.H.A., Lafaie, L., Langendoen, J.W., Larsen, T.B., Lifford, K., van der Linden, Y.M., Mahé, I., Maiorana, L., Maraveyas, A., Martens, E.S.L., Mayeur, D., van Mens, T.E., Mohr, K., Mooijaart, S.P., Murtagh, F.E.M., Nelson, A., Nielsen, P.B., Ording, A.G., Ørskov, M., Pearson, M., Poenou, G., Portielje, J.E.A., Raczkiewicz, D., Rasmussen, K., Trinks-Roerdink, E., Schippers, I., Seddon, K., Sexton, K., Sivell, S., Skjøth, F., Søgaard, M., Szmit, S., Trompet, S., Vassal, P., Visser, C., van Vliet, L.M., Wilson, E., Klok, F.A., and Noble, S.I.R.

Published
2023
Full Text
View/download PDF

5. Sex Differences in PrEsentation, Risk Factors, Drug and Interventional Therapies, and OUtcomes of Elderly PatientS with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study

Author

Bikdeli, Behnood, Piazza, Gregory, Jimenez, David, Muriel, Alfonso, Wang, Yun, Khairani, Candrika D., Rosovsky, Rachel P., Mehdipoor, Ghazaleh, O'Donoghue, Michelle L., Spagnolo, Primavera, Dreyer, Rachel P., Bertoletti, Laurent, López-Jiménez, Luciano, Núñez, Manuel Jesús, Blanco-Molina, Ángeles, Bates, Shannon M., Gerhard-Herman, Marie, Goldhaber, Samuel Z., Monreal, Manuel, and Krumholz, Harlan M.

Published
2022
Full Text
View/download PDF

16. Recovery from acute kidney injury in patients with pulmonary embolism: A single-center study

Author

Léa Fouillet, Adel Merah, Elodie De Magalhaes, Nathalie Moulin, Sandrine Accassat, Martin Murgier, Laurent Bertoletti, Cécile Duvillard, Patrick Mismetti, Manuel Monreal, and Edouard Ollier

Subjects
medicine.medical_specialty, business.industry, MEDLINE, Acute kidney injury, Hematology, Acute Kidney Injury, medicine.disease, Single Center, Pulmonary embolism, Surgery, Text mining, Acute Disease, medicine, Humans, In patient, Pulmonary Embolism, business
Published
2021
Full Text
View/download PDF

18. OC-14: Effectiveness and safety of 6-months' treatment with different full-dose enoxaparin regimens in patients with cancer-associated venous thromboembolism: a subgroup analysis of the RIETECAT cohort study

Author

Monreal, M., primary, Bertoletti, L., additional, López-Núñez, J.J., additional, Tiberio, G., additional, Soler, S., additional, Gómez-Cuervo, C., additional, Fidalgo, Á., additional, Mellado, M., additional, López-Miguel, P., additional, and Díaz-Peromingo, J.A., additional

Published
2022
Full Text
View/download PDF

20. PO-41: Cancer-associated thrombosis: how many patients seen in clinical practice would be eligible to a randomized controlled trial?

Author

Petit, B., primary, Soudet, S., additional, Poenou, G., additional, Zarrat, E., additional, Machuron, T., additional, Accassat, S., additional, Plaisance, L., additional, Helfer, H., additional, Mismetti, V., additional, Le Hello, C., additional, Sevestre, M.-A., additional, Mahé, I., additional, and Bertoletti, L., additional

Published
2022
Full Text
View/download PDF

21. PO-55: Effectiveness and safety of enoxaparin in the extended treatment of venous thromboembolism in active cancer patients with renal impairment: results from the RIETECAT-RI cohort study

Author

López-Núñez, J.J., primary, Trujillo-Santos, J., additional, Bertoletti, L., additional, Lobo, J.L., additional, Visonà, A., additional, Otero-Candelera, R., additional, Ruiz-Sada, P., additional, De Ancos, C., additional, Mahé, I., additional, and Monreal, M., additional

Published
2022
Full Text
View/download PDF

27. Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis

Author

S. Provencher, Patrice Nony, Silvy Laporte, Guillaume Grenet, Sabine Mainbourg, Laurent Bertoletti, Patrick Mismetti, Claire Grange, R. Kilo, François Gueyffier, Jean-Christophe Lega, Michel Cucherat, I. Durieu, Evaluation et modélisation des effets thérapeutiques, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Biologie intégrative du tissu osseux, Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Université Laval [Québec] (ULaval), Biologie Intégrative du Tissu Osseux (LBTO), Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Centre d'Investigation Clinique - Epidémiologie Clinique Saint-Etienne (CIC-EC), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), F-Crin Innovte [CHU Saint-Etienne], CHU Saint-Etienne, CIC Saint Etienne, Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Nord (Saint Etienne), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), and CCSD, Accord Elsevier

Subjects
Acute coronary syndrome, medicine.medical_specialty, Pyridones, Deep vein, [SDV]Life Sciences [q-bio], Administration, Oral, Hemorrhage, 030204 cardiovascular system & hematology, Major bleeding, Dabigatran, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Rivaroxaban, Edoxaban, Internal medicine, Atrial Fibrillation, Medicine, Humans, Risk of thrombosis, Dosing regimen, business.industry, Darexaban, Anticoagulants, Hematology, medicine.disease, 3. Good health, [SDV] Life Sciences [q-bio], Stroke, Regimen, Meta-analysis, medicine.anatomical_structure, Treatment Outcome, chemistry, 030220 oncology & carcinogenesis, Apixaban, business, medicine.drug, Direct oral anticoagulant
Abstract

International audience; Aim: The direct oral anticoagulants (DOAC) have similar half-lives, but the dosing regimen varies between once daily (QD) or twice daily (BID). For some prescribers, the QD regimen improves compliance. Others prefer BID regimens to promote better stability of plasma concentrations, particularly in the event of missed doses. Limited level of evidence provides guidance about the best treatment strategy. The purpose of this study was to compare the treatment effect of QD vs. BID administration of DOACs in major orthopedic surgery (MOS), non-valvular atrial fibrillation (NVAF), venous thromboembolism (VTE), and acute coronary syndrome (ACS).Methods: We conducted a systematic review up to April 2020. We included phase II clinical trials comparing DOAC QD vs BID with same daily dose. We extracted data for the occurrence of major thrombosis (proximal deep vein thrombosis, pulmonary embolism, myocardial infarction, ischemic stroke) and major hemorrhage (ISTH criteria and recommendations of the European Medicines Agency for surgical patients). Relative risks (RR) were combined using a fixed and random effects weighted meta-analysis.Results: Twelve randomized, controlled, phase II trials were included (10,716 patients), representing 24 dosing regimen comparisons of apixaban, darexaban, edoxaban, rivaroxaban, letaxaban, and dabigatran. There was no difference for major thrombotic event (RRBID/QD = 1.06, 95%IC 0.86-1.30) nor for major bleeding (RRBID/QD = 1.02, 95%IC 0.84-1.23) between the BID vs QD regimens, without heterogeneity (I2 = 0%).Conclusion: Our study does not support a global difference in term of efficacy and safety of the BID and QD regimens of DOAC in MOS, NVAF, VTE and ACS.

Published
2020
Full Text
View/download PDF

34. What's next after the clot? Residual pulmonary vascular obstruction after pulmonary embolism: From imaging finding to clinical consequences

Author

Judith Catella-Chatron, P.B. Bonnefoy, Laurent Bertoletti, Victor Margelidon-Cozzolino, E. Ayoub, Martin Murgier, J.B. Guichard, Biologie intégrative du tissu osseux, and Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Male, medicine.medical_specialty, [SDV]Life Sciences [q-bio], 030204 cardiovascular system & hematology, Scintigraphy, 03 medical and health sciences, 0302 clinical medicine, Quality of life, Risk Factors, Internal medicine, Medicine, Humans, Vascular Diseases, Lung, medicine.diagnostic_test, business.industry, Gold standard, Thrombosis, Hematology, medicine.disease, Pulmonary hypertension, 3. Good health, Pulmonary embolism, Embolism, 030220 oncology & carcinogenesis, Breathing, Cardiology, Female, business, Pulmonary Embolism, Perfusion
Abstract

Surviving an embolism exposes patients to potential long-term complications, such as altered quality of life, persistent dyspnea, impaired exercise capacity or pulmonary hypertension. The common objective factor in most of these situations is the presence of residual pulmonary vascular obstruction (RPVO). Planar ventilation/perfusion scintigraphy (V/Q lung scan) is the gold standard for assessing RPVO, which occurs in 46 to 66% of patients at 3 months and persists in 25 to 29% of patients a year after acute PE. Assessed early (i.e. before discharge), RPVO could predict acute PE development with a high negative predictive value. Evaluated after anticoagulation therapy, RPVO could help to manage anticoagulation treatment and predict the risk of PE recurrence and patients identified at risk of developing chronic thromboembolic pulmonary hypertension. In this comprehensive review, we provide an overview of the current knowledge of RPVO after PE from imaging diagnosis to clinical consequences. In the first part, we mainly focus on the imaging modalities capable of detecting and quantifying RPVO. We then focus on the symptoms and syndromes linked with this residual obstruction after PE. Although the occurrence of RPVO and long-term complications varies greatly from one patient to another, we finally aim to identify the patients and diseases at risk of developing residual obstruction.

Published
2019
Full Text
View/download PDF

35. The Ottawa score performs poorly in cancer patients with incidental pulmonary embolism

Author

Marcello Di Nisio, M. Biosca, Frits I. Mulder, Anthony Maraveyas, Laurent Bertoletti, Noémie Kraaijpoel, Harry R. Büller, Andrés Muñoz, Guy Meyer, Nick van Es, Isabelle Mahé, Vascular Medicine, ACS - Pulmonary hypertension & thrombosis, Graduate School, and Amsterdam Reproduction & Development (AR&D)

Subjects
Male, medicine.medical_specialty, medicine.drug_class, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Neoplasms, Medicine, Humans, Cumulative incidence, cardiovascular diseases, Aged, Framingham Risk Score, business.industry, Anticoagulant, Hazard ratio, Cancer, Anticoagulants, Hematology, Venous Thromboembolism, medicine.disease, Pulmonary embolism, 030220 oncology & carcinogenesis, Female, business, Pulmonary Embolism, Venous thromboembolism, Cohort study
Abstract

Background The Ottawa score was previously developed to predict recurrent venous thromboembolism (VTE) in cancer patients with VTE. The performance of this score in patients with incidental VTE is currently unclear. Aim To evaluate the performance of the Ottawa risk score in cancer patients with incidental pulmonary embolism included in an international, prospective, observational cohort study. Methods The score was used to classify patients as high (≥1), intermediate (0), or low risk (≤−1). The discriminative performance of the score was estimated by calculating the cumulative incidence of recurrent VTE for all groups, the time-dependent c-statistic, and the sub-distribution hazard ratio (SHR), using a competing risk approach. Results Of the 691 patients for which the Ottawa score could be calculated, 25 (3.6%) had recurrent VTE during 6-month follow-up and 38 (5.5%) during 12-month follow-up. The c-statistics of the continuous score at 6 and 12 months were 0.45 (95% CI, 0.36–0.54) and 0.51 (95% CI, 0.46–0.59), respectively. The 6-month cumulative incidences of recurrent VTE for those at low, intermediate, and high risk were 3.9% (95% CI, 1.5–8.4), 3.6% (95% CI, 1.9–6.2), and 3.6% (95% CI, 1.8–6.5), respectively. A sensitivity analysis restricted to the on-treatment period yielded similar results. None of the Ottawa risk score items were significantly associated with recurrent VTE. Conclusion In cancer patients with incidental pulmonary embolism, the Ottawa risk score has a poor predictive value for recurrent VTE, which does not support the use of the score in this patient population.

Published
2019

37. OC-15 Risk factors of recurrence in cancer-associated venous thromboembolism after discontinuation of anticoagulant therapy: a RIETE-based prospective study

Author

Adel Merah, F.X. Lapébie, Alessandra Bura-Rivière, Laurent Bertoletti, and M. Monreal

Subjects
medicine.medical_specialty, Anticoagulant therapy, business.industry, Internal medicine, medicine, Cancer, Hematology, Prospective cohort study, medicine.disease, business, Venous thromboembolism, Discontinuation
Published
2021
Full Text
View/download PDF

39. Outcomes during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis

Author

Tufano, Antonella, Ageno, Walter, Di Micco, P., Niglio, A., Rosa, V., Ballaz, A., Braester, A., Rubio, C. M., Isern, V., Imbalzano, E., Monreal, M., Adarraga, M. D., Aibar, M. A., Alfonso, M., Aranda, C., Arcelus, J. I., Barba, R., Barrón, M., Barrón-Andrés, B., Bascuñana, J., Blanco-Molina, A., Braun, B., Camon, A. M., Carrasco, C., Chasco, L., Cruz, A. J., Cuevas, G., de Miguel, J., del Pozo, R., del Toro, J., Díaz-Pedroche, M. C., Díaz-Peromingo, J. A., Falgá, C., Fernández-Aracil, C., Fernández-Capitán, C., Fernández-Muixi, J., Fidalgo, M. A., Font, C., Font, L., Furest, I., García, M. A., García-Bragado, F., García-Morillo, M., García-Raso, A., García-Rodenas, M., Gavín, O., Gómez, C., Gómez, V., González, J., Grau, E., Guijarro, R., Guirado, L., Gutiérrez, J., Hernández-Blasco, L., Hernando, E., Jara-Palomares, L., Jaras, M. J., Jiménez, D., Jiménez, R., Joya, M. D., Lima, J., Llamas, P., Lobo, J. L., López-Jiménez, L., López-Miguel, P., López-Reyes, R., López-Sáez, J. B., Lorente, M. A., Lorenzo, A., Loring, M., Lumbierres, M., Madridano, O., Maestre, A., Marchena, P. J., Martín, M., Martín-Martos, F., Morales, M. V., Nieto, J. A., Núñez, M. J., Olivares, M. C., Otalora, S., Otero, R., Pedrajas, J. M., Pellejero, G., Pérez-Ductor, C., Peris, M. L., Pons, I., Porras, J. A., Riera-Mestre, A., Rivas, A., Rodríguez-Dávila, M. A., Ruiz-Artacho, P., Sahuquillo, J. C., Sala-Sainz, M. C., Sampériz, A., Sánchez-Martínez, R., Sancho, T., Soler, S., Soto, M. J., Suriñach, J. M., Tolosa, C., Torres, M. I., Trujillo-Santos, J., Uresandi, F., Usandizaga, E., Valle, R., Vela, J., Villalobos, A., Vázquez, F. J., Vilaseca, A., Vanassche, T., Vandenbriele, C., Verhamme, P., Wells, P., Hirmerova, J., Malý, R., Salgado, E., Sánchez, G. T., Benzidia, I., Bertoletti, L., Bura-Riviere, A., Falvo, N., Farge-Bancel, D., Hij, A., Merah, A., Mahé, I., Moustafa, F., Quere, I., Brenner, B., Ellis, M., Tzoran, I., Antonucci, G., Bilora, F., Brandolin, B., Bucherini, E., Cattabiani, C., Ciammaichella, M., Dentali, F., Duce, R., Giorgi-Pierfranceschi, M., Grandone, E., Lessiani, G., Maggi, F., Maida, R., Mastroiacovo, D., Pace, F., Pesavento, R., Pinelli, M., Poggio, R., Prandoni, P., Quintavalla, R., Rocci, A., Siniscalchi, C., Tiraferri, E., Visonà, A., Zalunardo, B., Skride, A., Bosevski, M., Zdraveska, M., Bounameaux, H., Erdmann, A., Fresa, M., Mazzolai, L., and Caprini, J.

Subjects
Male, medicine.medical_specialty, Anticoagulant therapy, Bleeding, Recurrences, Splanchnic vein thrombosis, Anticoagulants, Female, Hemorrhage, Humans, Middle Aged, Recurrence, Splanchnic Circulation, Treatment Outcome, Venous Thrombosis, Hematology, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, medicine, In patient, Prothrombin time, medicine.diagnostic_test, business.industry, Hazard ratio, Cancer, medicine.disease, Surgery, 030220 oncology & carcinogenesis, business, Venous thromboembolism, Major bleeding
Abstract

Introduction Current guidelines recommend the use of anticoagulant therapy in patients with symptomatic splanchnic vein thrombosis (SVT) and suggest no routine anticoagulation in those with incidental SVT. Methods We used the RIETE (Registro Informatizado Enfermedad Trombo Embolica) registry to assess the rate and severity of symptomatic venous thromboembolism (VTE) recurrences and major bleeding events appearing during the course of anticoagulation in patients with symptomatic or incidental SVT. Results In March 2017, 521 patients with SVT were recruited. Of them, 212 (41%) presented with symptomatic SVT and 309 had incidental SVT. Most (93%) patients received anticoagulant therapy (median, 147 days). During the course of anticoagulation, 20 patients developed symptomatic VTE recurrences (none died) and 26 had major bleeding (fatal bleeding, 5). On multivariable analysis, patients with incidental SVT had a non-significantly higher risk for symptomatic VTE recurrences (adjusted hazard ratio [HR]: 2.04; 95%CI: 0.71–5.88) and a similar risk for major bleeding (HR: 1.12; 95%CI: 0.47–2.63) than those with symptomatic SVT. Active cancer was associated with at increased risk for VTE recurrences (HR: 3.06; 95%CI: 1.14–8.17) and anaemia (HR: 4.11; 95%CI: 1.45–11.6) or abnormal prothrombin time (HR: 4.10; 95%CI: 1.68–10.1) were associated with at increased risk for major bleeding. Conclusions The rates of recurrent SVT and major bleeding were similar between patients with incidental or symptomatic SVT. Because the severity of bleeding complications during anticoagulation may outweigh the severity of VTE recurrences in both groups, further studies should identify those SVT patients who benefit from anticoagulant therapy.

Published
2017

40. Practical issues in suspected venous thrombosis in general practice: A multicentre prospective cohort in primary care

Author

Emmanuel Chapelier, Patricia Fayard, Benjamin Seffert, Mouzayan Ginzarly, Béatrice Simon-Momège, Sébastien Bruel, Laurent Bertoletti, Paul Frappé, and Gustave investigators

Subjects
Adult, Male, medicine.medical_specialty, MEDLINE, Primary care, 030204 cardiovascular system & hematology, Cohort Studies, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Medicine, Humans, 030212 general & internal medicine, Prospective Studies, Young adult, Intensive care medicine, Prospective cohort study, Aged, Venous Thrombosis, Primary Health Care, business.industry, Hematology, Middle Aged, medicine.disease, Venous thrombosis, Multicenter study, General practice, Emergency medicine, Female, business, Cohort study
Published
2017

41. D-dimer levels and 90-day outcome in patients with acute pulmonary embolism with or without cancer

Author

Ana, Maestre, Javier Trujillo Santos, Adriana, Visoná, José Luís Lobo, Enric, Grau, Radovan, Malý, Rita, Duce, Manuel, Monreal, Alcalde, M, Arcelus, Ji, Ballaz, A, Barba, R, Barrón, M, Barrón Andrés, B, Bascuñana, J, Bedate, P, Blanco Molina, A, Bueso, T, Casado, I, Conget, F, del Molino, F, del Toro, J, Falgá, C, Fernández Capitán, C, Fuentes, Mi, Gallego, P, García, J, García Bragado, F, Gavín, O, Gómez, V, González, J, González Bachs, E, Grau, E, Guil, M, Guijarro, R, Gutiérrez, J, Hernández, L, Jara Palomares, L, Jaras, Mj, Jiménez, D, Jiménez, S, Lobo, Jl, López Jiménez, L, López Sáez JB, Lorente, Ma, Lorenzo, A, Luque, Jm, Madridano, O, Macià, M, Maestre, A, Marchena, Pj, Martín, M, Monreal, M, Mora, Jm, Muñoz, Fj, Nauffal, Md, Nieto, Ja, Núñez, Mj, Ogea, Jl, Otero, R, Pedrajas, Jm, Peris, Ml, Riera Mestre, A, Rivas, A, Rodríguez Dávila MA, Román, P, Rosa, V, Ruiz, J, Ruiz Ribó MD, Ruiz Gamietea, A, Ruiz Giménez, N, Sahuquillo, Jc, Samperiz, A, Sánchez Muñoz Torrero JF, Soler, S, Tiberio, G, Tilvan, Rm, Tolosa, C, Trujillo, J, Uresandi, F, Valdés, M, Valero, B, Valle, R, Vela, J, Vidal, G, Villalobos, A, Villalta, J, Malý, R, Hirmerova, J, Tomko, T, Bertoletti, L, Bura Riviere, A, Farge Bancel, D, Grange, C, Hij, A, Mahe, I, Merah, A, Quere, I, Schellong, S, Babalis, D, Papadakis, M, Tzinieris, I, Braester, A, Brenner, B, Tzoran, I, Zeltser, D, Barillari, G, Ciammaichella, M, Dalla Valle, F, Di Micco, P, Duce, R, Maida, R, Pasca, S, Piovella, C, Poggio, R, Prandoni, Paolo, Quintavalla, R, Rocci, A, Rota, L, Schenone, A, Tiraferri, E, Tonello, D, Tufano, A, Visonà, A, Zalunardo, B, Brinquinho, M, Gomes, D, Gonçalves, F, Santos, M, Saraiva, M, Bosevski, M, Kovacevic, D, Alatri, A, Aujeski, D, Bounameaux, H, Calanca, L, Mazzolai, L., Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Caractéristiques féminines des dysfonctions des interfaces cardio-vasculaires (EA 2992), and Université Montpellier 1 (UM1)-Université de Montpellier (UM)

Subjects
Male, medicine.medical_specialty, 030204 cardiovascular system & hematology, Gastroenterology, Fibrin Fibrinogen Degradation Products, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Neoplasms, Internal medicine, D-dimer, medicine, Humans, In patient, 030212 general & internal medicine, Aged, business.industry, Anticoagulants, Cancer, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, Prognosis, medicine.disease, 3. Good health, Pulmonary embolism, Quartile, Cardiology, Female, Registry data, Pulmonary Embolism, business
Abstract

International audience; BACKGROUND:The prognostic value of D-dimer testing in patients with acute pulmonary embolism (PE) has not been thoroughly studied.METHODS:We used the RIETE Registry data to assess the 90-day prognostic value of increased IL Test D-dimer levels at baseline in patients with PE, according to the presence or absence of cancer.RESULTS:As of May 2013, 3,283 patients with acute PE underwent D-dimer testing using IL Test D-dimer. Among 2,588 patients without cancer, those with D-dimer levels in the highest quartile had a higher rate of fatal PE (2.6% vs. 0.9%; p=0.002), fatal bleeding (1.1% vs. 0.3%; p=0.017) and all-cause death (9.1% vs. 4.4%; p

Published
2014
Full Text
View/download PDF

42. Treatment and long-term clinical outcomes of incidental pulmonary embolism in cancer patients: an international prospective cohort study

Author

N. Falvo, C. Tromeur, J. Schmidt, E. Confrere, N. Dublanchet, F. Piovella, M. Di Nisio, A.W. Rutjes, A. Muñoz, S. Accassat, Jan Beyer-Westendorf, M. Pinson, S.M. Bleker, R. Caliandro, F. Couturaud, I. Russi, J. Constans, M. Salgado Fernández, F. Lalezari, H.M. Otten, C. de Prado Maneiro, Marc Carrier, L. Bertoletti, J.D. Assaf, E. de Magalhaes, J.F. Bergmann, J. Baars, D. Iosub, Ettore Porreca, T. Lerede, S. Gonzàlez Santiago, P. Martinez Del Prado, G. Bozas, A. Kleinjan, N. Kraaijpoel, A.I. Ferrer Pérez, M.A. Sevestre, O. Sanchez, Anita Aggarwal, A. Rutten, C. Boulon, Anthony Maraveyas, B. Planquette, S. Aquilanti, A. Falanga, I. Désormais, M. Biosca, H.R. Büller, G. Meyer, S. Endig, C. Grange, P. Girard, J. Thaler, N. van Es, H. Helfer, Frederick R. Rickles, I. Mahé, P. Lacroix, I. García Escobar, N. Paleiron, L.F.M. Beenen, and Sandra Marten

Subjects
Pediatrics, medicine.medical_specialty, business.industry, medicine, Cancer, Hematology, medicine.disease, Prospective cohort study, business, Pulmonary embolism, Term (time)
Published
2018
Full Text
View/download PDF

43. In patients with cancer, prognostic factors of catheter-related thrombosis (CRT) are different than prognostic factors of VTE. A prospective cohort study in 3032 cancer patients with central venous catheter (ONCOCIP)

Author

Aurélie Bourmaud, Adel Merah, L. Bertoletti, P. Fournel, Silvy Laporte, Guy Meyer, Emilie Presles, Hervé Decousus, Franck Chauvin, C. Labruyere, G. Landry, and L. Stefani

Subjects
medicine.medical_specialty, business.industry, medicine.medical_treatment, Internal medicine, medicine, Cancer, In patient, Hematology, Catheter related thrombosis, Prospective cohort study, medicine.disease, business, Central venous catheter
Published
2018
Full Text
View/download PDF

44. Chronic thromboembolic pulmonary hypertension in cancer patients with pulmonary embolism

Author

Adel Merah, Sandrine Accassat, E. de Magalhaes, Judith Catella-Chatron, Laurent Bertoletti, Nathalie Moulin, Patrick Mismetti, and Cécile Duvillard

Subjects
medicine.medical_specialty, business.industry, Internal medicine, medicine, Cardiology, Cancer, Chronic thromboembolic pulmonary hypertension, Hematology, medicine.disease, business, Pulmonary embolism
Published
2018
Full Text
View/download PDF

45. In patients with cancer, prognostic factors of catheter-related thrombosis (CRT) are different than prognostic factors of VTE. A prospective cohort study in 3032 cancer patients with central venous catheter (ONCOCIP)

Author

Decousus, H., primary, Bertoletti, L., additional, Fournel, P., additional, Bourmaud, A., additional, Labruyère, C., additional, Presles, E., additional, Merah, A., additional, Laporte, S., additional, Stefani, L., additional, Landry, G., additional, Chauvin, F., additional, and Meyer, G., additional

Published
2018
Full Text
View/download PDF

46. Treatment and long-term clinical outcomes of incidental pulmonary embolism in cancer patients: an international prospective cohort study

Author

Kraaijpoel, N., primary, Bleker, S.M., additional, van Es, N., additional, Mahé, I., additional, Muñoz, A., additional, Meyer, G., additional, Planquette, B., additional, Sanchez, O., additional, Bertoletti, L., additional, Accassat, S., additional, de Magalhaes, E., additional, Baars, J., additional, Rutten, A., additional, Lalezari, F., additional, Beyer-Westendorf, J., additional, Endig, S., additional, Marten, S., additional, Porreca, E., additional, Rutjes, A.W., additional, Russi, I., additional, Constans, J., additional, Boulon, C., additional, Kleinjan, A., additional, Beenen, L.F.M., additional, Iosub, D., additional, Piovella, F., additional, Couturaud, F., additional, Tromeur, C., additional, Biosca, M., additional, Assaf, J.D., additional, Helfer, H., additional, Pinson, M., additional, Lerede, T., additional, Falanga, A., additional, Lacroix, P., additional, Désormais, I., additional, Maraveyas, A., additional, Bozas, G., additional, Aggarwal, A., additional, Rickles, F., additional, Girard, P., additional, Caliandro, R., additional, Martinez del Prado, P., additional, de Prado Maneiro, C., additional, García Escobar, I., additional, Gonzàlez Santiago, S., additional, Schmidt, J., additional, Dublanchet, N., additional, Aquilanti, S., additional, Confrere, E., additional, Paleiron, N., additional, Grange, C., additional, Sevestre, M.A., additional, Ferrer Pérez, A.I., additional, Salgado Fernández, M., additional, Falvo, N., additional, Thaler, J., additional, Otten, H.M., additional, Carrier, M., additional, Bergmann, J.F., additional, Büller, H.R., additional, and Di Nisio, M., additional

Published
2018
Full Text
View/download PDF

48. Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism

Author

José Antonio Nieto, Rosario, Solano, Natacha Trapero Iglesias, Nuria Ruiz Giménez, Carmen Fernández Capitán, Beatriz, Valero, Gregorio, Tiberio, Alessandra Bura Riviere, Manuel, Monreal, Monreal, M, Decousus, H, Prandoni, Paolo, Brenner, B, Barba, R, Di Micco, P, Bertoletti, L, Schellong, S, Papadakis, M, Tzoran, I, Reis, A, Bosevski, M, Bounameaux, H, Malý, R, Arcelus, Ji, Arroyo, M, Ballaz, A, Barrón, M, Barrón Andrés, B, Bascuñana, J, Bedate, P, Blanco Molina, A, Bueso, T, Casado, I, del Molino, F, del Toro, J, Falgá, C, Fernández Capitán, C, Fole, D, Gallego, P, García Bragado, F, Gavín, O, Gómez, V, González, J, González Bachs, E, Grau, E, Guil, M, Guijarro, R, Gutiérrez, J, Hernández, L, Hernández Huerta, S, Jara Palomares, L, Jaras, Mj, Jiménez, D, Lecumberri, R, Lobo, Jl, López Jiménez, L, López Sáez JB, Lorente, Ma, Lorenzo, A, Luque, Jm, Madridano, O, Maestre, A, Marchena, Pj, Martín Villasclaras JJ, Muñoz, Fj, Nauffal, Md, Nieto, Ja, Núñez, Mj, Ogea, Jl, Otero, R, Paul, He, Pedrajas, Jm, Peris, Ml, Quezada, Ca, Riera Mestre, A, Rivas, A, Rodríguez Dávila MA, Román, P, Rosa, V, Ruiz, J, Ruiz Gamietea, A, Ruiz Giménez, N, Sahuquillo, Jc, Samperiz, A, Sánchez Muñoz Torrero JF, Soler, S, Tiberio, G, Tolosa, C, Trujillo, J, Uresandi, F, Valdés, M, Valero, B, Valle, R, Vela, J, Vidal, G, Villalobos, A, Villalta, J, Hirmerova, J, Salgado, E, Sánchez, Gt, Bura Riviere, A, Farge Bancel, D, Mahe, I, Merah, A, Quere, I, Babalis, D, Tzinieris, I, Braester, A, Barillari, G, Ciammaichella, M, Duce, R, Maida, R, Pasca, S, Pesavento, R, Piovaccari, G, Piovella, C, Poggio, R, Prandoni, P, Quintavalla, R, Rota, L, Schenone, A, Tiraferri, E, Tonello, D, Tufano, A, Visonà, A, Zalunardo, B, Barbosa, Al, Gomes, D, Gonçalves, F, Santos, M, Saraiva, M, Alatri, A, Aujeski, D, Calanca, L, and Mazzolai, L.

Subjects
Male, medicine.medical_specialty, Databases, Factual, medicine.drug_class, Low molecular weight heparin, Hemorrhage, Fatal outcome, Cohort Studies, Predictive Value of Tests, Risk Factors, Thromboembolism, medicine, Humans, Survival rate, Aged, Aged, 80 and over, Framingham Risk Score, business.industry, Reproducibility of Results, Anticoagulants, Venous Thromboembolism, Odds ratio, Hematology, medicine.disease, Prognosis, Surgery, Pulmonary embolism, Survival Rate, Predictive value of tests, Cohort, Female, business, Cohort study
Abstract

SummaryBackgroundThe only available score to assess the risk for fatal bleeding in patients with venous thromboembolism (VTE) has not been validated yet.MethodsWe used the RIETE database to validate the risk-score for fatal bleeding within the first 3months of anticoagulation in a new cohort of patients recruited after the end of the former study. Accuracy was measured using the ROC curve analysis.ResultsAs of December 2011, 39,284 patients were recruited in RIETE. Of these, 15,206 had not been included in the former study, and were considered to validate the score. Within the first 3months of anticoagulation, 52 patients (0.34%; 95% CI: 0.27-0.45) died of bleeding. Patients with a risk score of 4 points had a rate of 1.44%. The c-statistic for fatal bleeding was 0.775 (95% CI 0.720-0.830). The score performed better for predicting gastrointestinal (c-statistic, 0.869; 95% CI: 0.810-0.928) than intracranial (c-statistic, 0.687; 95% CI: 0.568-0.806) fatal bleeding. The score value with highest combined sensitivity and specificity was 1.75. The risk for fatal bleeding was significantly increased (odds ratio: 7.6; 95% CI 3.7-16.2) above this cut-off value.ConclusionsThe accuracy of the score in this validation cohort was similar to the accuracy found in the index study. Interestingly, it performed better for predicting gastrointestinal than intracranial fatal bleeding.

Published
2013
Full Text
View/download PDF

49. Unsuspected pulmonary embolism in patients with cancer

Author

Silvia, Soler, Cristina, Delgado, Aitor, Ballaz, Elena, Cisneros, Radován, Malý, Dimitrios, Babalis, Manuel, Monréal, Decousus, H, Prandoni, Paolo, Brenner, B, Barba, R, Di Micco, P, Bertoletti, L, Papadakis, M, Bosevski, M, Bounameaux, H, Malý, R, Arcelus, Ji, Arcos, Mp, Ballaz, A, Barrón, M, Blanco Molina, A, Bosco, J, Chaves, E, Conget, F, Delgado, C, De Ancos, C, del Toro, J, Falgá, C, Farfán, A, Fernández Capitán, C, Gallego, P, García Bragado, F, Gómez del Olmo, V, Guijarro, J, Guillém, N, Gutiérrez, J, Hernández, L, Hernández Huerta, D, Jaras, Mj, Jiménez, D, Jiménez, S, Jiménez Gil, M, Lobo, Jl, López Jiménez, L, Lorenzo, A, Luque, Jm, Macia, M, Madridano, O, Maestre, A, Marchena, Pj, Martín Villasclaras JJ, Monreal, M, Morales, M, Nauffal, Md, Nieto, Ja, Ogea, Jl, Pedrajas, Jm, Riera Mestre, A, Rodríguez Dávila MA, Román, P, Román Bernal, B, Rosa, V, Ruíz, J, Ruiz Gamietea, A, Ruiz Giménez, N, Ruiz Ribó MD, Sahuquillo, Jc, Samperiz, A, Sánchez, R, Sánchez Muñoz Torrero JF, Soler, S, Soto, Mj, Tiberio, G, Todolí, Ja, Tolosa, C, Trujillo, J, Uresandi, F, Valdés, M, Valdés, V, Valle, R, Vidal, G, Villalta, J, Zorrilla, V, Bura Riviere, A, Debourdeau, P, Mahe, I, Babalis, D, Tzinieris, I, Barillari, A, Barillari, G, Ciammaichella, C, Dalla Valle, F, Maida, R, Pasca, S, Piovella, C, Poggio, R, Prandoni, P, Quintavalla, R, Schenone, A, Tonello, D, Visonà, A, and Tomko, T.

Subjects
Male, medicine.medical_specialty, Colorectal cancer, Comorbidity, Risk Assessment, Prostate, Neoplasms, Internal medicine, Prevalence, medicine, Humans, In patient, Registries, business.industry, Incidence (epidemiology), Anticoagulants, Cancer, Hematology, Prognosis, medicine.disease, Pulmonary embolism, Europe, Natural history, Treatment Outcome, medicine.anatomical_structure, Female, Radiology, Pulmonary Embolism, business
Abstract

Background The natural history of unsuspected pulmonary embolism (PE) in patients with cancer has not been thoroughly studied. Methods We used the RIETE Registry data to compare the clinical characteristics, treatment strategies and outcome in cancer patients with unsuspected PE and in those presenting with symptomatic, acute PE. Results Up to December 2011, 78 cancer patients with unsuspected PE and 1,994 with symptomatic PE had been enrolled. Patients with unsuspected PE more likely had colorectal cancer than those with symptomatic PE (28% vs. 13%), and less likely had prostate (3.8% vs. 10%) or hematologic (1.3% vs. 6.4%) cancer, or prior venous thromboembolism (3.8% vs. 12%). While the patients were receiving anticoagulant therapy, the incidence of PE recurrences (0% vs. 1.9%) or major bleeding (2.6% vs. 4.8%) were similar. After completion of anticoagulation, recurrent PE developed in 2.6% vs. 1.4% of patients, and major bleeding in 0% vs. 0.4%, respectively. Conclusions Our findings suggest that the clinical characteristics and outcome in cancer patients with unsuspected PE are quite similar to those in patients with symptomatic PE.

Published
2012
Full Text
View/download PDF

50. Seasonal variation in the superficial vein thrombosis frequency

Author

Déborah Peycelon, Laurent Bertoletti, Paul Frappé, Adel Merah, Andréa Buchmüller-Cordier, Bernard Tardy, Emilie Presles, and Hervé Decousus

Subjects
Male, Venous Thrombosis, medicine.medical_specialty, Superficial vein thrombosis, business.industry, Incidence (epidemiology), Absolute risk reduction, Retrospective cohort study, Hematology, Seasonality, Middle Aged, medicine.disease, Pulmonary embolism, Surgery, Venous thromboembolic disease, Relative risk, Internal medicine, medicine, Cardiology, Humans, Female, Seasons, business, Aged
Abstract

Introduction A seasonal variation of venous thromboembolic disease frequency is subject to discussion, and has been recently suggested for superficial vein thrombosis (SVT) in a small retrospective study. Our aim was to search for a seasonal variation of SVT frequency according to the data of larger studies. Materials and methods We analyzed the data of three French prospective multicenter studies with different designs which have included patients with SVT (STENOX, POST, and STEPH studies). Seasonal variation of SVT frequency was evaluated by comparing the observed seasonal frequency of SVT to a theoretical frequency of 25% for each season. Results The analysis included 1395 patients and 4.75 seasonal cycles. The difference to a theoretical frequency of 25% was statistically significant in one study (POST, p = 0.044). The higher risk difference was − 6.1% (95% CI − 11.7–−0.5) in summer in STENOX, + 7.1% (95% CI + 2.7–+11.5) in winter in POST and 4.2% (95% CI − 5.2–+13.7) in spring in STEPH, corresponding to a relative risk of 0.80, 1.40 and 1.20, respectively. Conclusions A seasonal variation was found in only one study which has the weakest methodology to warrant completeness. Variation pattern was different in each study. If this variation exists, it would probably be too low to have clinical consequences.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results